Statement of Practice Summary:
Antitrust, Appellate, Asia, Bankruptcy, Biotech, Pharma & Life Science, Chemicals, Collateralized Debt Obligation, Company Secretarial, Construction & Engineering, Corporate & Securities, Corporate Governance, Derivatives, E-commerce, Emerging Companies, Employee Benefits & Executive Compensation, Employee Share Incentives, Employment & Labour, Energy, Environment, Finance, Financial Services, Global Trade, Government, Government Contracts, Health Care, Information Technology, Insurance & Reinsurance, Intellectual Property, International Arbitration, Investment Management, Latin America, Legislative, Litigation & Dispute Resolution, Natural Resources, Outsourcing, Pensions, PPP/PFI & Infrastructure, Private Equity, Private Investment Fund, Pro Bono, Professional Practices, Project Finance, Property Rights, Public Law, Rail, Real Estate, Regulated Industries, Restructuring & Insolvency, Securitisation, Tax Controversy & Transfer Pricing, Tax Transactions & Consulting, Telecommunications & Media, Venture & Technology, Wealth Management.
EU Legislation Facilitates Antitrust Damages Litigation
Kiran S. Desai,Julian Ellison,Nathalie Jalabert Doury,Robert Klotz,Jens Peter Schmidt, December 2, 2014
Today's sign-off from the national governments in the EU is the final substantive step towards adoption by the EU of legislation on antitrust damages actions.
New Rules for Licence and other Technology Transfer Agreements in the EU
Kiran S. Desai,Nathalie Jalabert Doury,Robert Klotz,Jens Peter Schmidt,Ulrich Worm, April 2, 2014
The European Commission has just published the definitive text of the new rules on the interface between technology transfer agreements and antitrust law. This article looks at the main changes made by the new law which are likely to have a particular impact on the life sciences industry.